Dr hab. Marcin Waligóra, prof. UJ
W roku akademickim 2017/2018 przebywał na stypendium Fulbright Senior Award w Harvard Medical School Center for Bioethics.
Marcin Waligóra jest kierownikiem zespołu naukowego REMEDY, Research Ethics in Medicine Study Group.
W latach 2012-2016 pełnił funkcję członka Management Committee europejskiego projektu COST Disaster Bioethics: addressing ethical issues triggered by disasters.
Jest laureatem stypendium Minister Nauki i Szkolnictwa Wyższego dla wybitnych młodych naukowców (2014-2017) a także programu Fundacji na Rzecz Nauki Polskiej SKILLS – Mentoring (2014).
Prowadzi wykłady i seminaria z etyki, bioetyki i deontologii. Studiował na Uniwersytecie Jagiellońskim (doktorat w zakresie filozofii, 2007) oraz w International Academy of Philosophy w Santiago de Chile (2005).
Wybrane publikacje:
- Strzebonska K, Wasylewski MT, Zaborowska L, Polak M, Slugocka E, Stras J, Blukacz M, Gyawali B, Waligora M. Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. Target Oncol. 2021; 16(4):415-424. doi:10.1007/s11523-021-00822-5
- Wasylewski MT, Strzebonska K, Koperny M, Polak M, Kimmelman J, Waligora M (2020), Clinical development success rates and social value of pediatric Phase 1 trials in oncology, PLoS ONE 15(6): e0234911. doi: 10.1371/journal.pone.0234911
- Strzebonska K, Wasylewski MT, Zaborowska L, Riedel N, Wieschowski S, Strech D, Waligora M. Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis, BMJ Open. 2020 Jan 22;10(1):e034666. doi: 10.1136/bmjopen-2019-034666
- Strzebonska K, Waligora M, Umbrella and basket trials in oncology: ethical challenges, BMC Med Ethics. 2019 Aug 23;20(1):58. doi: 10.1186/s12910-019-0395-5
- Strzebonska K, Waligora M, Underestimation of Harms in Phase I Trials, The Journal of Law, Medicine & Ethics, 2019 Jun;47(2):334-335. doi: 10.1177/1073110519857290
- Kimmelman J, Waligora M, Fernandez Lynch H, Participants Protection in Phase1 Pediatric Cancer Trials, JAMA Pediatrics 2019;173(1):8-9. doi:10.1001/jamapediatrics.2018.3629
- Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J, Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis, PLoS Med 15(2): e1002505. doi: 10.1371/journal.pmed.1002505
- Waligora M, Strzebonska K, Wasylewski MT, Neither the Harm Principle nor the Best Interest Standard Should Be Applied to Pediatric Research, American Journal of Bioethics, 2018 Aug;18(8):72-74. doi: 10.1080/15265161.2018.1485762
- Piasecki J, Dranseika V, Waligora M, Should Epidemiological Studies Be Subject to Ethics Review?, Public Health Ethics, 2017, phx016. doi: 10.1093/phe/phx016
- Dranseika V, Gefenas E, Waligora M, Broadening the “Infrastructure Effect”: Lessons from the Early Development of Research Ethics in Eastern Europe, The American Journal of Bioethics, 2016 Jun; 16(6):26-8. doi: 10.1080/15265161.2016.1170243
- Mezinska S, Kakuk P, Mijaljica G, Waligóra M, O’Mathúna DP, Research in disaster settings: a systematic qualitative review of ethical guidelines, BMC Medical Ethics, 2016, 17:62. doi: 10.1186/s12910-016-0148-7
- Waligora M, Rozynska J, Piasecki J, Child’s objection to non-beneficial research: capacity and distress based models, Medicine, Health Care and Philosophy 2016 Mar;19(1):65-70. doi: 10.1007/s11019-015-9643-8
- M. Waligora, V. Dranseika, J. Piasecki, Child’s assent in research: Age threshold or personalisation?, BMC Medical Ethics 2014, 15:44. doi: 10.1186/1472-6939-15-44
- M. Waligora Failures in Clinical Trials in the European Union: Lessons from the Polish Experience, Science and Engineering Ethics 2013 Sep; 19(3):1087-98. doi:10.1007/s11948-012-9400-9
Więcej informacji na stronie remedy.edu.pl
